Is a New Protocol for Acute Lymphoblastic Leukemia Research or Standard Therapy?
Where this comes from
- Record sourced from PubMed, PMID 26283776.
- Also identified by DOI 10.1542/peds.2014-2327 and PMC identifier 4893943.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In the United States, doctors generally develop new cancer chemotherapy for children by testing innovative chemotherapy protocols against existing protocols in prospective randomized trials. In the Netherlands, children with leukemia are treated by protocols that are agreed upon by the Dutch Childhood Oncology Group. Periodically, the Dutch Childhood Oncology Group revises its protocols. Sometimes, these revisions are categorized as research, sometimes as treatment. In this Ethics Rounds, we analyze whether enrollment in a new protocol ought to be considered research and, if so, we discuss the implications of that designation. Our discussion highlights the different ways different countries approach complex issues of research ethics.
Medical subject headings
- Antineoplastic Combined Chemotherapy Protocols
- Clinical Protocols
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Therapeutic Human Experimentation